Pharma BD Deal Intelligence

I-MED Pharma Inc. / Kane Biotech Inc.

2024 · Licensing/Option · Complete

Kane Biotech granted I-MED Pharma an exclusive five-year worldwide license to incorporate its DispersinB biofilm-dispersing enzyme technology into eye care products for meibomian gland dysfunction and dry eye blepharitis syndrome. Kane described it as the first commercial agreement for DispersinB; terms include minimum annual royalties beginning in 2025, with amounts not disclosed.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2029 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2024 deals